TC BioPharm's Cancer Vaccine Fails to Impress Investors

TC Biopharm's TCBP Stock Plunges Over 60% After Disappointing Phase 2 Trial Results

March 25, 2023 - TC Biopharm (NASDAQ: TCBP) is trading sharply lower today after the company announced disappointing results from its Phase 2 trial for its lead candidate, TCB-4. The stock is down over 60% in early trading.

TC Biopharm's TCB-4 is a T-cell therapy designed to treat relapsed or refractory multiple myeloma. The company announced that the trial did not meet its primary endpoint, with patients who received TCB-4 showing no significant improvement in overall response rate compared to those who received standard of care.

Despite the disappointing results, TC Biopharm is not giving up on TCB-4 just yet. The company plans to conduct additional studies to better understand the results and determine the next steps for the program.

"The Phase 2 trial results are disappointing, but they do not define the potential of TCB-4," said Dr. Tomer Aviv, CEO of TC Biopharm. "We are committed to advancing this therapy and exploring its potential in multiple myeloma and other indications."

The stock's sharp decline is not surprising, given the lack of positive results from the Phase 2 trial. However, some investors may be willing to take a chance on TC Biopharm and its TCB-4 program, given the company's commitment to moving forward with additional studies.

TCBP is currently trading down 62% at $2.50 per share. The stock's decline is a significant setback for the company, but it may not be the end of the road for TCB-4 just yet.